Published in Bioconjug Chem on September 10, 2015
Rapid formation of a stable boron-nitrogen heterocycle in dilute, neutral aqueous solution for bioorthogonal coupling reactions. Chem Commun (Camb) (2015) 0.77
Stable and Potent Selenomab-Drug Conjugates. Cell Chem Biol (2017) 0.75
Improved variants of SrtA for site-specific conjugation on antibodies and proteins with high efficiency. Sci Rep (2016) 0.75
Development of a facile antibody-drug conjugate platform for increased stability and homogeneity. Chem Sci (2016) 0.75
Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates. MAbs (2017) 0.75
Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy. Adv Mater (2017) 0.75
Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med (2012) 9.17
FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94
A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. J Am Chem Soc (2004) 7.51
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol (2000) 6.63
Glutathione metabolism and its implications for health. J Nutr (2004) 6.27
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J (1978) 5.40
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res (2004) 3.16
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res (1992) 2.83
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol (2005) 2.82
Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol (2003) 2.75
Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol (2010) 2.67
Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res (2007) 2.48
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res (2001) 2.35
Methyl 4-mercaptobutyrimidate as a cleavable cross-linking reagent and its application to the Escherichia coli 30S ribosome. Biochemistry (1973) 2.14
Bioconjugation of ultrabright semiconducting polymer dots for specific cellular targeting. J Am Chem Soc (2010) 2.07
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol (2012) 2.06
Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem (2010) 2.06
Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl (2014) 2.01
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A (2012) 1.99
Protein modification, bioconjugation, and disulfide bridging using bromomaleimides. J Am Chem Soc (2010) 1.89
Rapid, stable, chemoselective labeling of thiols with Julia-Kocieński-like reagents: a serum-stable alternative to maleimide-based protein conjugation. Angew Chem Int Ed Engl (2013) 1.85
Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol (2013) 1.82
Development of a bioorthogonal and highly efficient conjugation method for quantum dots using tetrazine-norbornene cycloaddition. J Am Chem Soc (2010) 1.80
Site-specific antibody drug conjugates for cancer therapy. MAbs (2014) 1.74
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem (2006) 1.68
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
Prodrug strategies in anticancer chemotherapy. ChemMedChem (2008) 1.62
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem (2002) 1.59
Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem (2015) 1.58
In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano (2012) 1.53
Strictosidine synthase: mechanism of a Pictet-Spengler catalyzing enzyme. J Am Chem Soc (2008) 1.50
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 1.47
Combination cancer therapy: Presidential address. Cancer Res (1972) 1.47
Facile conversion of cysteine and alkyl cysteines to dehydroalanine on protein surfaces: versatile and switchable access to functionalized proteins. J Am Chem Soc (2008) 1.42
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol (1999) 1.41
Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat Protoc (2012) 1.40
Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem (2011) 1.40
In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano (2013) 1.34
Antibody-linked spherical nucleic acids for cellular targeting. J Am Chem Soc (2012) 1.34
Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl (2010) 1.31
Antibody-drug conjugates: current status and future directions. Drug Discov Today (2013) 1.29
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel (2006) 1.29
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem (2005) 1.28
A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem (2013) 1.23
A perfluoroaryl-cysteine S(N)Ar chemistry approach to unprotected peptide stapling. J Am Chem Soc (2013) 1.23
New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res (1987) 1.19
Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug Chem (2011) 1.18
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol (2005) 1.17
A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. Anal Biochem (1983) 1.17
Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs (2011) 1.17
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia (2002) 1.14
Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials (2011) 1.14
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods (2008) 1.11
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res (2010) 1.11
Site-specific antibody-drug conjugation through glycoengineering. Bioconjug Chem (2014) 1.10
A direct method for site-specific protein acetylation. Angew Chem Int Ed Engl (2011) 1.08
Biocompatible functionalization of polymersome surfaces: a new approach to surface immobilization and cell targeting using polymersomes. J Am Chem Soc (2011) 1.06
Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci U S A (1986) 1.06
Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem (2014) 1.05
Polymer nanogels: a versatile nanoscopic drug delivery platform. Adv Drug Deliv Rev (2012) 1.05
Novel therapeutic strategies to selectively kill cancer cells. Biochem Pharmacol (1998) 1.04
Fluorescent-labeled antibodies: Balancing functionality and degree of labeling. Anal Biochem (2010) 1.03
Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano (2011) 1.03
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther (2012) 1.03
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
A Pictet-Spengler ligation for protein chemical modification. Proc Natl Acad Sci U S A (2012) 0.99
Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug Chem (2013) 0.98
Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol Ther (2011) 0.97
Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug Chem (2014) 0.97
Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. Bioconjug Chem (2014) 0.97
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem (2002) 0.96
Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc (2012) 0.95
Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation. Bioconjug Chem (2013) 0.95
Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochem Pharmacol (1996) 0.94
Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett (1998) 0.93
Introduction of sulfhydryl groups into proteins using acetylmercaptosuccinic anhydride. Arch Biochem Biophys (1962) 0.93
A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl (2011) 0.91
Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model. Small (2013) 0.90
Site-specific protein transamination using N-methylpyridinium-4-carboxaldehyde. J Am Chem Soc (2013) 0.88
Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother Pharmacol (2007) 0.88
Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am J Respir Crit Care Med (1994) 0.87
Allenamides as orthogonal handles for selective modification of cysteine in peptides and proteins. Angew Chem Int Ed Engl (2014) 0.86
Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas. Clin Pharmacol Ther (1990) 0.84
Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format. Chem Commun (Camb) (2012) 0.84
Identification and localization of unpaired cysteine residues in monoclonal antibodies by fluorescence labeling and mass spectrometry. Anal Chem (2009) 0.83
Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives. Pathobiology (2005) 0.82
The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res (1991) 0.82
Protein reactions with methyl and ethyl vinyl sulfones. J Protein Chem (1988) 0.81